"Medizinische Klinik und Poliklinik III LMU - Klinikum der Universität München"
Welcome,         Profile    Billing    Logout  
 19 Trials 
19 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Heinemann, Volker
NCT00440167: Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine

Checkmark Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer - translational results from the AIO-PK0104 Phase 3 study.
Checkmark Intratumoral Bacterial Lipopolysaccharide (LPS) Detection as Negative Predictor of Gemcitabine Efficacy in Advanced Pancreatic Cancer: Translational Results from the AIO-PK0104 Phase 3 Study
Checkmark In pts with adv pancreatic cancer
Checkmark ASCO-GI 2013
Checkmark P3 data
More
Active, not recruiting
3
280
Europe
Gemcitabine, Capecitabine, Erlotinib
PD Dr. med. Volker Heinemann, Roche Pharma AG
Pancreatic Cancer
12/11
12/12
XELAVIRI, NCT01249638 / 2009-013099-38: Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC

Checkmark Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110).
Checkmark Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial).
Checkmark Gender and survival benefit from initial irinotecan in metastatic colorectal cancer: Analysis of the XELAVIRI (AIOKRK0110)- study.
Checkmark Gender and survival benefit from initial irinotecan in metastatic colorectal cancer: Analysis of the XELAVIRI (AIOKRK0110) study.
Checkmark Gender and survival benefit from initial irinotecan in metastatic colorectal cancer: Analysis of the XELAVIRI (AIOKRK0110) study.
More
Recruiting
3
516
Europe
Capecitabine, Bevacizumab, Irinotecan
Ludwig-Maximilians - University of Munich, Roche Pharma AG
Colorectal Cancer Metastatic
12/13
12/16
FIRE-3, NCT00433927: 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)

Checkmark FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
Checkmark [VIRTUAL] Evaluation of conversion therapy in patients undergoing secondary resection of metastases in curative intent within the FIRE-3 (AIO KRK-0306) study
Checkmark Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
Checkmark [VIRTUAL] Prognostic importance of primary tumor resection and synchronous metastasis on overall survival in metastatic colorectal cancer: Data from the FIRE-3 (AIO KRK-0306) study.
Checkmark Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
More
Active, not recruiting
3
568
Europe
5-FU, folinic acid, irinotecan, cetuximab, bevacizumab
PD Dr. med. Volker Heinemann, Merck KGaA
Neoplasm Metastasis, Colorectal Cancer
04/14
12/16
FIRE-4, NCT02934529 / 2014-003787-21: Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab

Recruiting
3
550
Europe
Irinotecan, Campto, Folinic Acid, Folgamma mono, 5-FU, Fluorouracil, Cetuximab, Erbitux, Bevacizumab, Avastin, Capecitabine, Xeloda, regorafenib, CAS #:755037-03-7, Irinotecan 125mg, Cetuximab wkly
Ludwig-Maximilians - University of Munich, Merck Serono GmbH
Metastatic Colorectal Cancer
03/20
03/22
RAMTAS, NCT03520946 / 2017-004162-99: RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

Checkmark [VIRTUAL] RAMucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic colorectal cancer: Safety results from the phase IIb part of the RAMTAS phase II/III trial of the German AIO (AIO-KRK-0316).
Checkmark [VIRTUAL] Interim safety analysis of the phase IIb study of ramucirumab in combination with TAS102 vs. TAS102 monotherapy in metastatic colorectal cancer: The RAMTAS trial of the German AIO
Checkmark A Phase IIb study of ramucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic, chemotherapy refractory colorectal cancer patients: The RAMTAS trial of the German AIO (KRK-0316).
Recruiting
3
426
Europe
Ramucirumab, TAS 102
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Eli Lilly and Company, Trium Analysis Online GmbH
Colorectal Cancer
12/23
06/24
PARLIM, NCT01384994 / 2010-023671-26: Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients

Checkmark [VIRTUAL] FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases: The PARLIM trial (AIO KRK 0314).
 
2
111
Europe
Folic Acid, 5-FU, Oxaliplatin, Panitumumab
PD Dr. med. Volker Heinemann, Amgen
Colorectal Cancer, KRAS Wildtype, After Resection of Liver Metastases
08/13
08/14
NCT01729481 / 2011-005471-17: Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer

Checkmark Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Checkmark Efficacy of gemcitabine with erlotinib in rash-positive patients selected according to eligibility for FOLFIRINOX.
Active, not recruiting
2
150
Europe
Gemcitabine, Gemzar, Erlotinib, Tarceva, Oxaliplatin, Eloxatin, Folinic Acid, Leucovorin, Irinotecan, Campto, 5-FU, 5-Flourouracil
Ludwig-Maximilians - University of Munich, Roche Pharma AG
Metastatic Pancreatic Adenocarcinoma
07/15
12/17
ACCEPT, NCT01728818: Afatinib as Cancer Therapy for Exocrine Pancreatic Tumours

Checkmark Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of …
Checkmark Gemcitabine plus afatinib versus gemcitabine alone in metastatic pancreatic cancer: an explorative randomized AIO phase II trial (ACCEPT)
Active, not recruiting
2
119
Europe
Gemcitabine, Afatinib
PD Dr. med. Volker Heinemann, Boehringer Ingelheim
Focus of Study Instead
01/17
01/18
INNOVATION, NCT02205047 / 2014-000722-38: Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma

Checkmark EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction aden…
Checkmark EORTC-1203: Integration of trastuzumab, with or without pertuzumab, into perioperative chemotherapy of HER-2 positive stomach cancer: INNOVATION EudraCT number 2014-000722-38; NCT02205047
Recruiting
2
220
Europe, RoW
Cisplatin, 5-fluorouracil or Capecitabine, Trastuzumab, Pertuzumab, gastrectomy
European Organisation for Research and Treatment of Cancer - EORTC, European Organization for the Research and Treatment of Cancer (EORTC), F. Hoffmann-La Roche, European Organisation for Research and Treatment of Cancer (EORTC), EORTC
Malignant Neoplasm of Stomach, Malignant Neoplasm of Cardio-esophageal Junction of Stomach, Epidermal Growth Factor Receptor (EGFR) Protein Overexpression
09/20
09/24
NCT03530267: Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer

Recruiting
2
196
Europe
Aflibercept + mLV5FU2, mFOLFOX7
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, STABIL - Statistische und Biometrische Lösungen, Trium Analysis Online GmbH, Sanofi
Colorectal Cancer
03/22
09/22
FOOTPATH, NCT03487016: First-line Therapy in Metastatic PDAC

Recruiting
2
270
Europe
Gemcitabine, Gemzar, Nab-paclitaxel, Abraxane, 5-FU, 5-Fluoruracil, Irinotecan Liposomal Injection, Onivyde, Oxaliplatin, Trans-l-diaminocyclohexanoxalatoplatin
Ludwig-Maximilians - University of Munich
Metastatic Pancreatic Cancer
06/22
06/23
AIO-STO-0417, NCT03647969 / 2017-002080-18: Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer

Checkmark [VIRTUAL] Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction – Safety Results from AIO-STO-0417: A randomized phase .…
Checkmark Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Moonlight, a randomized phase II trial of the German Gastric Grou…
Checkmark Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Moonlight, a randomized phase 2 trial of the German Gastric Group…
Recruiting
2
257
Europe
Nivolumab, Ipilimumab, mFOLFOX, FLOT
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Adenocarcinoma of the Stomach, GastroEsophageal Cancer
07/22
12/22
AIO-KRK-0116, NCT04034459: FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC

Checkmark [VIRTUAL] Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116).
Recruiting
2
99
Europe
Bevacizumab, Irinotecan, Folinic acid, Oxaliplatin, 5-FU, Cetuximab
Ludwig-Maximilians - University of Munich
Metastatic Colorectal Cancer
11/22
12/23
NCT04034173: Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation

Not yet recruiting
2
120
Europe
Panitumumab, Irinotecan, Folinic acid, 5-FU
Ludwig-Maximilians - University of Munich, Amgen, ClinAssess GmbH
Treatment Related Cancer
08/24
08/26
AFFECT, NCT02975141: Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer

Active, not recruiting
1
12
Europe
Afatinib 30Mg Tab, Giotrif, Afatinib 40Mg Tab, Gemzar, Gemcitabine, Abraxane, nab-Paclitaxel
PD Dr. med. Volker Heinemann, Technische Universität München, University of Cologne
Metastatic Pancreatic Cancer
12/18
06/19
NCT01448668: Iscador Qu as Supportive Treatment in Pancreatic Cancer (Union for International Cancer Control, UICC Stages II-IV)

 
N/A
220
Europe
IFAG AG, Hiscia Society for Cancer Research, IFAG Basel AG, both Switzerland
Pancreas Cancer
12/15
06/16
NCT01448655: Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)

Recruiting
N/A
300
Europe
IFAG AG, Hiscia Society for Cancer Research, IFAG Basel AG (CRO), both Switzerland
Colorectal Cancer
12/16
06/17
TRacKING, NCT04921553: Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions

Recruiting
N/A
500
Europe, RoW
Data collection and quality of life questionnaire
Centre Leon Berard
Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression, NTRK Family Gene Mutation, ATIC-ALK Fusion Protein Expression, ALK Fusion Protein Expression, BCR-FGFR1 Fusion Protein Expression, ROS1 Gene Translocation, COL1A1-PDGFB Fusion Protein Expression, RET Gene Translocation, Gene Fusion, ROS Gene Translocation, BRAF Gene Rearrangement, FGFR2 Gene Translocation, FGFR3 Gene Translocation, NTRK1 Gene Translocation
06/25
06/25
NCT04852250: Centralized Tumour Board and Secondary Intervention Rate in mCRC

Not yet recruiting
N/A
130
NA
Virtual centralized multidisciplinary tumour board
Ludwig-Maximilians - University of Munich, Charité Universitätsmedizin, Department of Hematology, Oncology and Tumor Immunology
Metastatic Colorectal Cancer, RAS Mutation, Multidisciplinary Communication, Secondary Intervention
03/23
03/25

Download Options